TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05563909

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Patients participating in the study will not receive any intervention other than exercise and splint.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wrist Splint
Description: Patients participating in the study will not receive any intervention other than exercise and splint.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wrist Splint
Description: Patients participating in the study will not receive any intervention other than exercise and splint.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wrist Splint
Description: Patients participating in the study will not receive any intervention other than exercise and splint.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Mediated Exercise
Description: Patients participating in the study will not receive any intervention other than exercise and splint.
Study: NCT04812366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide 60mg Tab
Description: 4 tablets by mouth once a day for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide 60mg Tab
Description: 4 tablets by mouth once a day for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide 60mg Tab
Description: 4 tablets by mouth once a day for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate 250mg
Description: 4 tablets by mouth on an empty stomach once a day for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate 250mg
Description: 4 tablets by mouth on an empty stomach once a day for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate 250mg
Description: 4 tablets by mouth on an empty stomach once a day for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate 250mg
Description: 4 tablets by mouth on an empty stomach once a day for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone 5mg Tab
Description: 1 tablet by mouth once daily while taking abiraterone acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone 5mg Tab
Description: 1 tablet by mouth once daily while taking abiraterone acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone 5mg Tab
Description: 1 tablet by mouth once daily while taking abiraterone acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone 5mg Tab
Description: 1 tablet by mouth once daily while taking abiraterone acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Infusion every 3 weeks for 6 cycles (each cycle has 3 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niraparib 100mg Oral Capsule
Description: 3 capsules by mouth once daily for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: 1200mg infusion every 3 weeks for 6 cycles
Study: NCT05930197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate
Description: BSS is a commonly used, widely available, OTC medication for a variety of gastrointestinal GI symptoms. It is available in the generic form, but also under the more commonly known brands: Bismatrol; Diotame; Geri-Pectate; Kao-Tin; Peptic Relief; Pepto-Bismol; Pink Bismuth and Stomach Relief. It received approval by the US Food and Drug Administration (FDA) in 1939.
Study: NCT05713201

Intervention type: PROCEDURE
Intervention: Percutaneous Coronary Intervention
Description: Treatment of coronary stenoses with a drug-eluting stent or balloon

Intervention type: PROCEDURE
Intervention: Percutaneous Coronary Intervention
Description: Treatment of coronary stenoses with a drug-eluting stent or balloon
Study: NCT04786028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Brand name for interventional drug is Sarclisa
Study: NCT05672602

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of ncRNAs and cytokines
Description: Measurement of lncRNAs in PBMCs samples and miRNAs in plasma samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of ncRNAs and cytokines
Description: Measurement of lncRNAs in PBMCs samples and miRNAs in plasma samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of ncRNAs and cytokines
Description: Measurement of lncRNAs in PBMCs samples and miRNAs in plasma samples.
Study: NCT06162143

Intervention type: DEVICE
Intervention: Gelsectan®
Description: Gelsectan® is a CE-marked class II device containing xyloglucans, xylo-oligosaccharides, pea proteins, and tannins from grape seeds extract, already used in Irritable Bowel Syndrome (IBS).
Study: NCT05746182

Intervention type: DIAGNOSTIC_TEST
Intervention: Hereditary Cancer Panel
Description: UCSF's Internal Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified Expanded Hereditary Cancer Panel will be employed which measures a minimum 88 genes
Study: NCT05086016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheterized Stenting
Description: Catheterized stenting of vascular narrowings.
Study: NCT05680337

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: TENS stimulation will occur within 10 minutes. HRV parameters will be evaluated before stimulation initially at rest, in the first 5 minutes of stimulation, in the second 5 minutes of stimulation and after the end of stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS
Description: TENS stimulation will occur within 10 minutes. HRV parameters will be evaluated before stimulation initially at rest, in the first 5 minutes of stimulation, in the second 5 minutes of stimulation and after the end of stimulation.
Study: NCT05383664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultra Violet Light Exposure
Description: Subjects will stand at the determined distance from the UV lamps facing towards them to achieve full body UV exposure. They will stand for the time indicated to achieve the appropriate dose. Each exposure will range from about 1 minute to 4.5 minutes to deliver a dose ranging from 0.22J/cm2 to 0.88J/cm2. Subjects will then rotate to irradiate their back side for the same time to achieve the same dose. On the second visit clinical examination will be conducted for erythema. If no erythema is apparent, the dosage on subsequent visits may increase to the max of 0.88 J/cm2.
Study: NCT05878119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigational Product - MIB 626
Description: The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigational Product - MIB 626
Description: The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized, progressive, high intensity, multidimensional exercise
Description: Participants will be asked to perform high intensity, standardized, progressive, multidimensional exercise.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standardized, progressive, high intensity, multidimensional exercise
Description: Participants will be asked to perform high intensity, standardized, progressive, multidimensional exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Physical Activity
Description: Participants will be asked to perform usual physical activity per listed in the protocol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Physical Activity
Description: Participants will be asked to perform usual physical activity per listed in the protocol
Study: NCT05774756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Solution for daily subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to setmelanotide for daily subcutaneous injection
Study: NCT06555419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nusinersen
Description: Administered as specified in the treatment arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ThecaFlex DRx System
Description: Implantated as specified in the treatment arm.
Study: NCT06639256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product HY07121
Description: HY07121 should be administered intravenously at recommended dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product HY07121
Description: HY07121 should be administered intravenously at recommended dose.
Study: NCT06490705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tongue resistance exercises, tongue strengthening exercises and tongue resistance exercises
Description: 6 days a week, 3 times a day (before meals), with each session lasting 30 minutes. Don't hold your breath during exercise.~Before conducting the study, all participants received a complete explanation of the purpose, risks, and procedures of the investigation, and provided written informed consent. Procedures were in accordance with the ethical standards of the committee on human experimentation at the institution at which the work was conducted and this study was approved by the Institutional Review Board.
Study: NCT03878316

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Instranasal Oxytocin
Description: Intranasal Oxytocin - concentrated formulation - 35 IU per dose
Study: NCT06490705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tongue resistance exercises, tongue strengthening exercises and tongue resistance exercises
Description: 6 days a week, 3 times a day (before meals), with each session lasting 30 minutes. Don't hold your breath during exercise.~Before conducting the study, all participants received a complete explanation of the purpose, risks, and procedures of the investigation, and provided written informed consent. Procedures were in accordance with the ethical standards of the committee on human experimentation at the institution at which the work was conducted and this study was approved by the Institutional Review Board.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tongue resistance exercises, tongue strengthening exercises and tongue resistance exercises
Description: 6 days a week, 3 times a day (before meals), with each session lasting 30 minutes. Don't hold your breath during exercise.~Before conducting the study, all participants received a complete explanation of the purpose, risks, and procedures of the investigation, and provided written informed consent. Procedures were in accordance with the ethical standards of the committee on human experimentation at the institution at which the work was conducted and this study was approved by the Institutional Review Board.
Study: NCT03878316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Instranasal Oxytocin
Description: Intranasal Oxytocin - concentrated formulation - 35 IU per dose
Study: NCT05514405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam (Byfavo)
Description: Remimazolam is continuously infused based on bispectral index (within 40-60).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is continuously infused based on bispectral index (within 40-60).
Study: NCT05720130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [²¹²Pb]Pb-ADVC001
Description: Ph1b Escalation~Drug: \[²¹²Pb\]Pb-ADVC001administered intravenously per dose escalation scheme~Dose Level 1~- 60 MBq, 4 cycles every 6 weeks~Dose Level 2a~- 120 MBq, 4 to 6 cycles every 4 weeks~Dose Level 2b~- Optional cohort of 120 MBq, 4 to 6 cycles every 2 weeks~Dose Level 3a~- 160 MBq, 4 to 6 cycles every 4 weeks~Dose Level 3b~- Optional cohort of 160 MBq, 4 to 6 cycles every 2 weeks~Dose Level 4a~- 200 MBq, 4 to 6 cycles every 4 weeks~Dose Level 4b~- Optional cohort of 200 MBq, 4 to 6 cycles every 2 weeks~Ph2a Expansion~Drug: \[²¹²Pb\]Pb-ADVC001 at recommended phase 2 dose and schedule
Study: NCT04523922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 IU Intranasal Oxytocin
Description: 40 IU Intranasal Oxytocin self administered 30 minutes prior to each COPE session.
Study: NCT05197907

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascial release of diaphragm muscle.
Description: The intervention consists of deep tissue massage techniques and manual mobilization of the fascia performed within the diaphragm attachments in the area of the costal arches.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Classic massage of the abdomen.
Description: The intervention consists of selected classic massage techniques - mainly stroking (effleurage) - performed on the superficial layers of the abdominal region
Study: NCT06102629

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy / laparotomy
Description: 1. We will take both blood and ovarian tissue samples used to diagnosis.~2. We will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (surgical profile) before their planned surgery or for disease evaluation.~3. Small tissue samples (from ovary) will be taken from the tissue which is surgically excised as a part of treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NO INTERVENTION
Description: .We will take both blood and ovarian tissue samples used to diagnosis. 2.We will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (surgical profile) before their planned surgery or for disease evaluation.~3. Small tissue samples (from ovary) will be taken from the tissue which is surgically excised as a part of treatment.
Study: NCT05478993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD：Selinexor Oral Tablet, Pomalidomide, Dexamethasone
Description: Patients diagnosed with multiple myeloma with CNS involvement to receive Selinexor (60 mg QW), pomalidomide (4 mg/day, on Days 1-21), and dexamethasone (40 mg/day, on Days 1, 8, 15, 22), with all agents dosed 28 days per cycle.~If patients reach maximum efficacy and have received SPD treatment for 8-12 cycles, maintenance treatment of Selinexor (20-60mg QW, optimal dose determined by the investigator) will be started and continued until disease progression or intolerable adverse events.
Study: NCT04523922

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo (intranasal saline spray) self administered 30 minutes prior to each COPE session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure
Description: 12 weekly sessions of COPE therapy for PTSD and AUD.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure
Description: 12 weekly sessions of COPE therapy for PTSD and AUD.
Study: NCT05849051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Newly developed warnings with images at 30% size
Description: On study days 1-6, 8-13 and 15-20, participants in this condition will view an image of a little cigar and cigarillo package with a warning developed by the study team that includes an image. The warnings will take up 30% of the package. Participants will view a total of 6 different warnings over the course of 6 days each week, this will be repeated 3 times during the study, resulting in a total of 18 exposures. Participants will be required to view the warning for at least 5 seconds.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FDA proposed text-only warnings at 30% size
Description: On study days 1-6, 8-13 and 15-20, participants in this condition will view an image of a little cigar and cigarillo package with a warning proposed by the FDA which is text only. The warnings will take up 30% of the package. Participants will view a total of 6 different warnings over the course of 6 days each week, this will be repeated 3 times during the study, resulting in a total of 18 exposures. Participants will be required to view the warning for at least 5 seconds.
Study: NCT04551521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 960 mg twice daily during run-in Phase, followed by 720 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: 60 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: 60 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 840 mg every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 840 mg every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg per kilogram of body weight as a loading dose, followed by 6 mg per kilogram every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg as a loading dose, followed by 420 mg intravenously every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: 600 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: 400 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg in the first cycle, followed by 840 mg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1,200 mg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: 9 mg once daily
Study: NCT05081180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants with primary CNS malignancies who have received at least 1 prior therapy will be enrolled into Dose Escalation Part 1 and will receive intravenous infusion at a flat dose or weight based dose of Avelumab, every 2 weeks (Q2W) until progression, unacceptable toxicity, or withdrawal of consent. Enrollment into part 1 of the study will end when Maximum tolerated dose (MTD) and/or a safe Recommended Dose for Expansion (RDE) for the expansion cohort is determined. Participants with defined CNS tumors will be enrolled into Dose Expansion Part 2 and will receive RDE in Part 2 until progression, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Participants with primary CNS malignancies who have received at least 1 prior therapy will be enrolled into Dose Escalation Part 1 and will receive daily oral escalated dose level of Lenvatinib until progression, unacceptable toxicity, or withdrawal of consent. Enrollment into part 1 of the study will end when MTD and/or a safe Recommended Dose for Expansion (RDE) for the expansion cohort is determined. Participants with defined CNS tumors will be enrolled into Dose Expansion Part 2 and will receive RDE of Lenvatinib in Part 2 until progression, unacceptable toxicity, or withdrawal of consent.
Study: NCT05789862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling Sessions
Description: Virtual sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaires
Description: Self administered questionnaires
Study: NCT06285773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RIFPB block
Description: For RIFPB, a local anesthetic will be injected into the plane between the costal cartilage and the rectus abdominis muscle at the 6th-7th costal cartilage under US guidance. The in-plane technique will be used. After confirming the block location, 10 ml of 0.25% concentration marcaine (bupivacaine) will be used (bilateral).

Intervention type: OTHER
Group type: OTHER
Intervention: Postoperative analgesia management
Description: Patients will be administered 10mg/kg paracetamol in the postoperative period every eight hours.~If the NRS score is ≥ 4, 1 mg kg-1 iv tramadol will be administered as a rescue analgesic.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia management
Description: Patients will be administered 10mg/kg paracetamol in the postoperative period every eight hours.~If the NRS score is ≥ 4, 1 mg kg-1 iv tramadol will be administered as a rescue analgesic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PIFPB block
Description: For PIFPB; the ultrasound probe for PIFB is placed 2-3 cm lateral to the upper third of the sternum, parallel to the sternum. A local anesthetic of 15 ml of 0.25% concentration of marcaine (bupivacaine) will be used between the pectoralis major and external intercostal muscles (bilateral).
Study: NCT06554444

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Implant Surgery
Description: Dental implants will be placed in edentulous areas.
Study: NCT05754918

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TnoFs then TFS (Cochlear implant)
Description: Cochlear implant with tonotopy-based fitting without fine structure coding then with fine structure coding

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TFS then TnoFS (Cochlear implant)
Description: Cochlear implant with tonotopy-based fitting with fine structure coding then without fine structure coding